β-defensin 38 inhibitors are a class of compounds that interact specifically with β-defensin 38, a member of the defensin family of small, cysteine-rich cationic proteins. β-defensins are predominantly known for their role in innate immunity, acting as antimicrobial peptides that help protect against bacterial, fungal, and viral pathogens. However, beyond their antimicrobial activity, β-defensins, including β-defensin 38, are implicated in a variety of biological processes, such as modulating inflammation, signaling pathways, and influencing cellular functions. Inhibitors of β-defensin 38 can interfere with these non-microbial activities, potentially modulating its interactions with other molecular components in the cellular environment. The specificity and efficacy of β-defensin 38 inhibitors are dependent on their ability to bind to the peptide with high affinity, preventing it from exerting its natural functions. These interactions are complex, often involving key structural motifs or domains within the β-defensin molecule, such as the cysteine-stabilized α/β motifs, which are critical for its bioactivity.
Chemically, β-defensin 38 inhibitors can vary widely in structure, from small molecules to peptides, each with distinct mechanisms of action. Some inhibitors may work by directly binding to the active site of β-defensin 38, thereby preventing it from interacting with its target receptors or substrates, while others might function by altering the folding or stability of the peptide, thus impeding its function. Structural studies, such as X-ray crystallography or NMR spectroscopy, are often employed to elucidate the binding interactions and to design more effective inhibitors. Moreover, computational modeling and molecular dynamics simulations have become crucial tools for understanding the binding affinities and conformational changes that occur upon inhibitor binding. These studies help to map the interaction surfaces and identify key residues that are critical for binding, which is invaluable for the design and optimization of novel inhibitors. Understanding the chemical characteristics and binding dynamics of β-defensin 38 inhibitors is essential for elucidating their roles in modulating the diverse biological activities of β-defensin 38, ultimately contributing to a broader understanding of the regulatory mechanisms of β-defensins in physiological contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $206.00 $299.00 $485.00 | 10 | |
PARP inhibitor disrupting DNA repair. Olaparib indirectly inhibits β-defensin 38 by interfering with the DNA damage response pathway, impacting the regulation of β-defensin 38 transcription under conditions of cellular stress. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
PI3K inhibitor disrupting the PI3K/AKT pathway. LY294002 indirectly hampers β-defensin 38, as PI3K/AKT signaling is implicated in the regulation of β-defensin 38 transcription by modulating specific transcription factors. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Calcineurin inhibitor affecting the NFAT pathway. Cyclosporin A indirectly inhibits β-defensin 38 by blocking NFAT activation, a key regulator of β-defensin 38 transcription in response to various stimuli. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor influencing the MAPK/ERK pathway. Trametinib indirectly influences β-defensin 38 expression by disrupting the MAPK/ERK pathway, which modulates β-defensin 38 transcription through specific downstream effectors. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
JNK inhibitor affecting the AP-1 pathway. SP600125 indirectly hinders β-defensin 38, as the AP-1 transcription factor, downstream of JNK, is involved in the transcriptional regulation of β-defensin 38. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
HDAC inhibitor modulating chromatin structure. Vorinostat indirectly suppresses β-defensin 38 by altering histone acetylation, influencing the accessibility of the β-defensin 38 gene for transcription. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
Wnt/β-catenin pathway inhibitor. XAV939 indirectly inhibits β-defensin 38, as the Wnt/β-catenin pathway is implicated in regulating β-defensin 38 expression by modulating the activity of specific transcription factors. | ||||||
Deferoxamine mesylate | 138-14-7 | sc-203331 sc-203331A sc-203331B sc-203331C sc-203331D | 1 g 5 g 10 g 50 g 100 g | $255.00 $1039.00 $2866.00 $4306.00 $8170.00 | 19 | |
HIF-1α inhibitor affecting the hypoxia pathway. Deferoxamine indirectly suppresses β-defensin 38, as HIF-1α enhances β-defensin 38 transcription under hypoxic conditions, and inhibiting HIF-1α disrupts this regulatory mechanism. | ||||||
Eprosartan | 133040-01-4 | sc-207631 | 10 mg | $166.00 | 1 | |
TLR4 inhibitor affecting the TLR4 signaling pathway. CLI-095 indirectly hampers β-defensin 38, as TLR4 activation is known to upregulate β-defensin 38 expression through NF-κB and AP-1 signaling cascades. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTOR inhibitor influencing the mTORC1 pathway. Rapamycin indirectly inhibits β-defensin 38 by modulating mTORC1 signaling, which is implicated in the regulation of β-defensin 38 through control of translation initiation. | ||||||